Hims & Hers Health Surges 38.7% in Volume to 23rd in Liquidity Amid 73% Revenue Jump

Hims & Hers Health (HIMS) rose 1.28% on August 4, with a trading volume of $2.34 billion, marking a 38.72% surge from the previous day’s activity, ranking 23rd in market liquidity. The stock’s performance coincided with the company’s Q2 2025 earnings report, which highlighted a 73% year-over-year revenue increase to $544.8 million, driven by a 31% rise in subscribers to 2.4 million. Net income reached $42.5 million, while adjusted EBITDA doubled to $82.2 million. The firm reaffirmed its full-year revenue guidance of $2.3 billion to $2.4 billion and adjusted EBITDA guidance of $295 million to $335 million.

Leadership emphasized strategic expansion into high-impact medical specialties to broaden the platform’s offerings. CEO Andrew Dudum noted the company’s role in advancing personalized care, while CFO Yemi Okupe highlighted investments in pharmacy personalization, lab testing, and international growth. The Q2 results underscored sustained momentum in subscription-based models, with personalized treatment plans adopted by nearly 1.5 million customers, reflecting 89% year-over-year growth. The company’s focus on precision medicine and operational scalability positions it to capitalize on evolving healthcare demands.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This outperformance underscores the impact of liquidity concentration and market volatility on short-term performance, with high-volume stocks like HIMS benefiting from institutional and algorithmic trading dynamics. The results highlight the potential for liquidity-driven strategies to amplify returns in volatile markets, particularly when aligned with high-demand sectors.